Chicago - October 22, 2021: At this year’s ASTRO 2021 event, GE Healthcare will showcase over 15 innovative multi-modality radiation therapy solutions, offering medical practitioners imaging tools and support they need to improve patient-centered care and advance the practice of precision medicine.
“GE Healthcare aims to drive improved patient outcomes through cutting-edge multi-modality radiation therapy planning and guidance solutions. Our expertise in clinical workflows, deep learning image reconstruction and image segmentation, and precision analytics can help support the delivery of more efficient, precise and personalized care," said Jan Makela, President & CEO, Imaging at GE Healthcare.
GE Healthcare’s precision radiation oncology technologies, including those listed below, provide clinicians with images and information for precise tailoring of treatments.
Below are highlights that GE Healthcare will be showcasing at ASTRO 2021 from October 24th to 27th:
● Vysioneer VBrain: GE Healthcare is proud to announce its collaboration with Vysioneer. Vysioneer’s VBrain solution applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma. VBrain demonstrates 12.2 percent higher sensitivity for lesion detection while decreasing treatment planning time at a median of 30.8 percent. VBrain is vendor-neutral, integrating with different treatment planning systems by supporting data routing to and from DICOM nodes within a hospital network. 
● Spectronic Medical Synthetic CT, MR auto-segmentation: GE Healthcare will integrate Spectronic Medical AB’s AI-based software for more precise cancer treatment planning. This AI solution, in combination with GE Healthcare’s advanced AIR Recon DL technology, offers a deep learning solution and radiation therapy treatment planning alternative to standard CT images. The combined solution begins with GE Healthcare’s AIR Recon DL, a deep learning image reconstruction technology that leverages raw data from the MR scanner to reduce image noise, maximize image quality and resolution, and shorten scan times. The high-quality MR images generated by the GE scanner are then converted into synthetic CT images by Spectronic Medical’s AI-based solution, providing clinicians with the CT images they have come to expect with MR soft tissue details to more accurately target lesions and help improve patient outcomes.
● Mirada RTx: As a part of their strategic collaboration to improve outcomes for patients, GE Healthcare and Mirada Medical are focusing on advancing automation and Artificial Intelligence (AI) technologies to enable faster, more consistent and more precise cancer radiotherapy treatment. To do so, the Mirada Medical RTx product has been integrated into the GE Healthcare AW Workstation and AW Server to enable enhanced cancer visualization and diagnostic capabilities. These integrations result in increased automation to deliver improvements in care workflows and help drive efficiency and time savings.
● Discovery MI Gen 2: GE Healthcare’s Discovery MI Gen 2 brings together the high sensitivity of digital detection with the company’s industry-first CT image reconstruction technology: Deep Learning Image Reconstruction for TrueFidelity CT Images. Generated using a dedicated deep neural network, TrueFidelity CT Images have the potential to improve reading confidence in a wide range of clinical applications such as head, whole body and cardiovascular, for patients across age groups.. The system also offers Q.Clear for up to 2x improvement in image quality (SNR) as well as MotionFree for up to 67 percent improvement in lesion volume measurements.
● Revolution Platform: GE Healthcare's family of intelligent CT scanners helps clinicians plan treatments to deliver more precise and efficient RT imaging solutions. The powerful Revolution platform is built on the wide-coverage Gemstone Clarity detector, Deep Learning Image Reconstruction and Gemstone Spectral Imaging to deliver superb clarity for optimizing treatment planning and diagnostic images. It empowers clinicians to stay ahead of the curve in an increasingly competitive market with scalable solutions that broaden healthcare system capabilities today and tomorrow.
● Discovery RT Gen 3: Discovery RT is a wide-bore scanner providing a thorough approach to radiation therapy planning. In addition to providing a streamlined workflow and sub-millimetric images that are effectively free of motion and metal artifacts, the system also allows for simulation across an 80 cm wide bore with 80 cm field of view reconstruction. Discovery RT expands capabilities to also meet specific needs in diagnostic, interventional and bariatric imaging.
Through these and a variety of additional solutions, GE Healthcare aims to further reinforce its role as a core partner in multidisciplinary cancer care and provide increasingly accessible, more precise, and high-value radiation therapy.
GE Healthcare will be exhibiting at booth 1337 from October 24th to 27th.
About GE Healthcare
GE Healthcare is the $17 billion* healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 47,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improving outcomes for patients, providers, health systems and researchers around the world.
+44 7887 824201
+1 608 381 8829
 Spectronic Medical MRI Planner Software is CE marked and 510(k) pending at U.S. FDA. Not available in all markets.
 Discovery MI Gen 2 has the highest NEMA sensitivity in its class in the market, compared to common PET/CT systems with the same or similar AFOV (based on IMV’s Medical Information Division’s 2019 report as the manufacturers representing more than 90% of the U.S. Installed Base).
 As demonstrated in phantom testing using a typical and fast respiratory model and OSEM reconstruction. Quantitative accuracy improvements are based on SUV mean.